NMRANeumora Therapeutics, Inc.同业对比
Neumora Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NMRA本股 | $108M#7 | — | 2.4x#10 | — | — | -2.8%#8 | — | 532.2%#2 | -594.0%#3 | — | -80.8%#4 | — |
| HUMA | $122M#1 | — | 3.9x#12 | 59.7x#7 | — | 72.5%#4 | -5306.0%#7 | -130.6%#13 | — | — | -72.4%#3 | — |
| ARMP | $114M#2 | — | — | — | — | -818.8%#15 | — | — | — | — | -35.9%#1 | 0.1%#1 |
| VYGR | $113M#3 | — | 0.7x#3 | 2.8x#5 | -49.5%#5 | -84.2%#12 | -326.6%#5 | -77.6%#11 | — | — | -59.9%#2 | — |
| AVXL | $112M#4 | — | 1.0x#6 | — | — | -7.8%#9 | — | -41.2%#7 | — | — | — | — |
| LENZ | $110M#5 | — | 0.6x#2 | 5.8x#6 | — | -65.0%#10 | -477.5%#6 | -42.8%#8 | — | — | — | — |
| ENGN | $109M#6 | 0.6x#1 | 0.5x#1 | — | — | -112.7%#13 | — | -50.9%#9 | — | — | — | — |
| BDTX | $104M#8 | — | 1.1x#7 | 1.5x#4 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | — | — |
| ATRA | $85M#9 | — | — | 0.7x#2 | -6.3%#3 | 138.3%#1 | 29.7%#1 | — | — | — | — | — |
| TNYA | $82M#10 | — | 1.2x#8 | — | — | 18.5%#6 | — | -130.5%#12 | — | — | — | — |
| VXRT | $80M#11 | 2.0x#2 | 1.0x#4 | 0.3x#1 | 726.7%#1 | 124.4%#3 | 7.6%#3 | 0.0%#3 | 22.5%#1 | — | — | — |
| CSBR | $68M#12 | — | 17.5x#13 | 1.1x#3 | 4.4%#2 | -125.0%#14 | -1.9%#4 | -0.0%#4 | — | — | — | — |
| CRDF | $67M#13 | — | 2.5x#11 | 112.6x#8 | -13.2%#4 | -0.9%#7 | -8256.3%#8 | -0.2%#5 | — | — | — | — |
| CGTX | $66M#14 | — | 2.0x#9 | — | — | 30.9%#5 | — | -71.1%#10 | — | — | — | — |
| GRMLW | $57M#15 | — | 1.0x#5 | — | — | -71.6%#11 | — | -18.2%#6 | -14.6%#2 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议